APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)
Study sponsor: Aprea Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2020-11-27Actual
Enrollment · participants154Actual
Source updated2025-03-18Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.